International Angiology最新文献

{"title":"Same-day discharge following endovascular peripheral interventions.","authors":"Faisal M Shaikh, Hannah Cliffe, Canice O'Mahony, Andrew Swali, Laszlo Papp","doi":"10.23736/S0392-9590.25.05474-4","DOIUrl":"https://doi.org/10.23736/S0392-9590.25.05474-4","url":null,"abstract":"<p><strong>Background: </strong>Recently, day case peripheral endovascular interventions have gained momentum due to constantly optimizing results, based on technological and pharmacological advancements. Despite this, some hospitals, especially in rural areas with limited access to the emergency services, have not fully adopted this model. We evaluate the safety and feasibility of same-day discharge after endovascular procedures in north wales hospitals.</p><p><strong>Methods: </strong>A study was conducted of patients who underwent day-case peripheral arterial endovascular interventions during two distinct 12-month periods: April 2019 to March 2020 and April 2021 to March 2022. Data were sourced from a prospectively maintained interventional radiology database. We defined procedural technical success as the successful distal arterial access and crossing of the target lesion. The primary endpoint was safe same-day discharge, and the secondary endpoint was any adverse event related to the intervention. Patient's demographics, clinical information (including indication: claudication versus critical limb ischemia), primary procedure details, technical success, procedural complications, and unplanned admissions were recorded. Patient's records were evaluated at a minimum of 12 months post procedure.</p><p><strong>Results: </strong>Over 24-month period, 221 patients underwent 237 peripheral arterial interventions as day case. The mean age was 70 years with male female ratio of 2:1. The indications for intervention were claudication (55%) and critical limb ischemia (45%). The mean distance to hospital from home address was 23.6 kilometers. The most common artery undergoing treatment was the superficial femoral artery (51%). The procedure technical success rate was 90%. There were 12 (5%) complications with three (1.3%) patients requiring open surgery. The unplanned hospital admissions rate was 7.2%. The primary endpoint of safe same-day discharge was achieved in 92.8% of cases.</p><p><strong>Conclusions: </strong>Same day discharge following peripheral endovascular interventions is safe and feasible even in a rural setting. With a low rate of complications and unplanned admissions this model of care can be adopted universally.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":"44 6","pages":"497-502"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neovascularization, a cause of truncal varicose vein recurrence after endovenous laser ablation.","authors":"Irwin V Mohan, Gaorui Liu","doi":"10.23736/S0392-9590.25.05417-3","DOIUrl":"https://doi.org/10.23736/S0392-9590.25.05417-3","url":null,"abstract":"<p><strong>Background: </strong>Endovenous ablation techniques (EVA) have become increasingly common and have taken the place of surgical treatment for truncal vein incompetence. We set out to investigate and identify outcome, complications, and incidence of recurrence, and possible causes of truncal recurrence in patients treated with Endovenous Laser Ablation (EVLA).</p><p><strong>Methods: </strong>A cohort study of 307 consecutive patients (119M/188F) with varicose veins and great saphenous vein incompetence, (C3-C6), were treated with EVLA. Clinical and duplex ultrasound assessment was performed for all patients. Post-procedure patients were placed in compression stockings for 2 weeks, and given enoxaparin for DVT prophylaxis. Patients were also assessed for deep venous thrombosis (DVT), and successful obliteration.</p><p><strong>Results: </strong>Median initial vein diameter was 6.9 (range 3.7-12.6) mm, and the median ablation energy was 57.8 (range 44.3 to 83.1) J/cm in all 307 patients. Complete truncal occlusion was noted in 301 patients. Truncal occlusion was demonstrated in all patients at initial and 2-week scan, however six patients with were noted to have developed truncal recurrence observed at 6-weeks to 3-months. The median energy delivered was 40.9 (range 35.6 to 41.7) J/cm, significantly less compared to non-recurrent GSV (P=0.02). We observed multiple tiny arteriovenous fistulae with arterialized signals within the lasered vein that became confluent, resulting in truncal recurrence.</p><p><strong>Conclusions: </strong>Venous re-canalization after EVLA occurs as a result of neovascularization. This takes the form of multiple tiny AV fistulae, that eventually join and becomes a confluent reflux. The triggers for this phenomenon are unclear, but probably related to linear endovenous energy density.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":"44 6","pages":"437-444"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of micronized purified flavonoid fraction on venous symptoms and signs in patients at all stages of chronic venous disease: a systematic review and meta-analysis. Part I: symptoms.","authors":"Andrew Nicolaides, Kirill Lobastov, Armando Mansilha, Alejandro J Gonzalez-Ochoa, Vanessa Blanc-Guillemaud, Marie-Blanche Onselaer, Soumeya Serifou, Hurrem P Yaltirik, Narayanan Sriram, Lianrui Guo, Stavros Kakkos","doi":"10.23736/S0392-9590.25.05462-8","DOIUrl":"10.23736/S0392-9590.25.05462-8","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic venous disease (CVD) significantly impacts patients' quality of life through leg symptoms and signs. This systematic literature review and meta-analysis, published in two separate articles, evaluated the effects of micronized purified flavonoid fraction (MPFF), a venoactive drug, on CVD symptoms and signs by analyzing data from a wide spectrum of clinical studies in patients with CVD at all stages of the disease. Part I presented herein, focused on symptoms, and Part II on signs.</p><p><strong>Evidence acquisition: </strong>A systematic review was conducted in November 2023 using PRISMA guidelines. Medline, Embase, and Cochrane databases were searched. Eligible studies included prospective randomized controlled trials (RCTs) and non-RCTs investigating the effects of oral MPFF treatment (1000 mg, daily for at least 1 month) on venous leg symptoms and signs in patients with CVD at all stages (C0s-C6). In the present analysis, primary outcomes were the main venous symptoms including pain, heaviness, discomfort, cramps, feeling of swelling, and burning sensation. Secondary outcomes were pruritus, paresthesia, fatigue, and global symptoms. Patient level of satisfaction with treatment was also assessed. A single-group random-effects meta-analysis was used to estimate the mean change in symptom intensity and the proportion of complete symptom resolution from baseline to the last post-baseline value.</p><p><strong>Evidence synthesis: </strong>Out of 387 articles, 56 studies were included in the analysis, among which 51 studies involving 39,878 MPFF-treated patients, reported CVD symptoms. Significant reductions in symptom intensity scores were observed for all outcomes (P<0.001), except for fatigue. Improvement of symptoms was further supported by the resolution of pain, heaviness, cramps, discomfort, and burning sensation observed in pooled estimated proportion of patients (76.2%, 61.5%, 80.5%, 69.8%, and 67.2%, respectively; all P<0.001). The overall level of patient satisfaction was estimated to be more than 90%. Twenty studies had high risk of bias, while sensitivity analyses did not change the study results. Heterogeneity level was frequently high among studies.</p><p><strong>Conclusions: </strong>This systematic review and meta-analysis provide strong evidence of consistent and clinically significant improvements in venous leg symptoms associated with the use of the venoactive drug MPFF, across all stages of CVD.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"445-468"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145648379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and tolerability of venoactive drugs combined with compression therapy in the treatment of chronic venous disease CEAP class C6: a prospective, observational study.","authors":"Vadim Y Bogachev, Boris V Boldin, Pavel Y Turkin, Alexandr Samenkov, Olga Dzhenina, Olga Linnik, Boris Kvasnikov","doi":"10.23736/S0392-9590.25.05353-2","DOIUrl":"10.23736/S0392-9590.25.05353-2","url":null,"abstract":"<p><strong>Background: </strong>Leg ulcers associated with chronic venous disease (CVD) are characterized by prolonged healing and high recurrence. This study describes the effectiveness and tolerability of venoactive drugs (VAD) combined with compression as part of conservative therapy for active venous leg ulcers among patients treated in routine clinical practice.</p><p><strong>Methods: </strong>This prospective, multicenter, observational, 6-month study recruited patients diagnosed with Clinical, Etiology, Anatomy, and Pathophysiology (CEAP) clinical class C6 and active venous ulcer area, 5-30 cm². VAD pharmacotherapy was at the discretion of the treating physician and consistent with national guidelines at the time of the study. Primary outcome was the proportion of patients with a healed venous ulcer at 6 months. Change from baseline in the mean Venous Clinical Severity Score (VCSS), the proportion of patients with a reduction in CEAP clinical class, and Quality of life (QoL - Chronic Venous Insufficiency Questionnaire [CIVIQ-14]) were also assessed.</p><p><strong>Results: </strong>The study enrolled 349 patients: 66.8% were women; mean age was 61.0±12.7 years; and mean Body Mass Index (BMI) was 27.9±4.1 kg/m². Mean duration of the reference venous ulcer was 18.3±23.0 weeks and mean ulcer area was 9.2±6.9 cm². All patients were prescribed VAD at baseline, most commonly micronized purified flavonoid fraction (MPFF) (98.3% patients). Compression therapy was prescribed to 91.1% of patients. After 6 months, venous ulcers had completely healed in 69.6% of patients; 13.5% had experienced complete healing at 3 months. Mean physician-assessed VCSS decreased from 15.5±4.1 at baseline to 9.7±4.5 at 6 months (P<0.001). There was a progressive decrease in mean reference ulcer area from 9.2±6.9 cm² at baseline to 1.2±2.8 cm² at 6 months. QoL was significantly improved with a reduction in mean CIVIQ-14 global index score from 53.9±20.5 at baseline to 24.5±16.3 at 6 months (P<0.001). Treatment was well tolerated.</p><p><strong>Conclusions: </strong>Combined treatment with VAD and compression therapy was associated with complete venous leg ulcer healing in 70% of patients with a mean time to healing of 7.4 months. A significant improvement in QoL compared with baseline was also observed.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"427-436"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of dual therapy with Aspirin and rivaroxaban in symptomatic peripheral artery disease: the DOLOMITI experience.","authors":"Luca Ferretto, Marco Penzo, Riccardo Bozza, Francesca Ghirardini, Romeo C Martini","doi":"10.23736/S0392-9590.25.05447-1","DOIUrl":"10.23736/S0392-9590.25.05447-1","url":null,"abstract":"<p><strong>Background: </strong>Peripheral artery disease (PAD) increases cardiovascular (CV) mortality risk. Dual therapy (DT) with aspirin and rivaroxaban reduces major CV adverse events and limb ischemia. An analysis of patients at high CV risk undergoing DT was conducted in a real-world setting. Major adverse events and bleedings were collected, comparing results with COMPASS and XATOA trials.</p><p><strong>Methods: </strong>A retrospective, observational, monocentric analysis was performed. Major-adverse-cardiovascular-events (MACE) and major-adverse-limb-events (MALE) defined the effectiveness of DT, whereases safety was assessed recording major and minor bleedings, according to the ISTH criteria. Blood pressure (BP), low-density-lipoprotein (LDL) levels, Rutherford's classes, Ankle-Brachial-Index (ABI) and Toe-Brachial-Index (TBI) were also evaluated.</p><p><strong>Results: </strong>Fifty-seven patients were considered from 2021 to 2024. The average follow-up was 24.5±10.1 months. The cumulative risk at 32 months of MACE, MALE and major or minor bleedings were 4.3%, 11% and 17.7% respectively. Comparing results with COMPASS and XATOA studies, there were more MALE, more minor bleedings and less MACE in DOLOMITI. There were more smokers, diabetics, hypertensives, patients with hypercholesterolemia, and patients with a history of limb revascularization in DOLOMITI. No differences in BP values were noticed at baseline and final valuations in DOLOMITI, whereases a reduction in LDL levels, an improvement in Rutherford's class, ABI and TBI resulted significative.</p><p><strong>Conclusions: </strong>Low-dose rivaroxaban and acetylsalicylic acid have shown efficacy in reducing MACE in real-world contexts, with acceptable MALE events and bleeding risk. DT maximizes benefits by optimizing CV risk factors and improving PAD symptoms, but targeted studies are needed.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":"44 6","pages":"486-496"},"PeriodicalIF":1.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145793298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of kinking and residual plaque ulcers after carotid artery stenting: differences between closed stent design and double-layer stents.","authors":"Carmine Poliseno, Rodolfo Pini, Marcello Lodato, Enrico Gallitto, Betti Shyti, Andrea Vacirca, Mauro Gargiulo, Gianluca Faggioli","doi":"10.23736/S0392-9590.25.05477-X","DOIUrl":"10.23736/S0392-9590.25.05477-X","url":null,"abstract":"<p><strong>Background: </strong>Carotid stenting (CAS) is an established alternative to carotid endarterectomy for asymptomatic and symptomatic stenosis. However, morphological features possibly appearing after CAS, such as carotid tortuosity/kinking and plaque ulcers underneath the stent (PuUS) remain under investigated. This study evaluates the impact of these factors on postoperative neurological risks, according to the type of stent implanted, i.e. closed stent design (CSD) versus double-layer stents (DLS).</p><p><strong>Methods: </strong>A single center retrospective evaluation of all consecutive CAS from 2004 to 2022 was performed. Cerebral protection filters devices were routinely employed, and traditional CSD (Wallstents, Boston Scientific, Natick, MA, USA) until 2015, followed by DLSs (Roadsaver, Terumo Corp., Tokyo, Japan). Stroke rates at 30 days and 1 year were assessed, focusing on stent-determined carotid kinking (angle >90°) and the presence of residual plaque ulcers underneath the deployed stent.</p><p><strong>Results: </strong>A total of 644 CAS patients (27% symptomatic) were analyzed. The procedure achieved a technical success rate of 96%, with a significantly higher stroke rate in symptomatic compared to asymptomatic patients (5.8% vs. 2.1%, P=0.01). Post-stent carotid kinking (4.2%) and residual plaque ulcers (8.4%) were more frequent with DLS than CSD (P=0.04 and P=0.001). Residual ulcers increased 30-day stroke risk (13% vs. 2.2%, P<0.001) but not post-CAS kinking (2.7% vs. 3.1%, P=0.92). DLS showed no strokes with residual ulcers at 30 days and 1 year (P=0.0001 and P=0.03, respectively), differently from CSD (19%).</p><p><strong>Conclusions: </strong>DLS are associated with a higher rate of stent determined distal internal carotid kinking and residual plaque ulcers but demonstrate a protective effect, minimizing stroke risk from plaque ulcers compared to CSD. These findings support the use of DLS to reduce cerebral embolization.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":"44 5","pages":"409-414"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145495447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative risk factors for acute compartment syndrome in non-traumatic acute lower limb ischemia.","authors":"Poon Apichartpiyakul, Jiraporn Khorana, Kittipan Rerkasem, Apichat Tantraworasin","doi":"10.23736/S0392-9590.25.05415-X","DOIUrl":"10.23736/S0392-9590.25.05415-X","url":null,"abstract":"<p><strong>Background: </strong>Post-reperfusion compartment syndrome (CS) is a serious complication that may occur after the revascularization of patients with acute limb ischemia (ALI). This study aims to explore the risk factors associated with CS, providing additional insights that can assist surgeons in making decisions regarding the necessity of prophylactic fasciotomy or intensive monitoring post-revascularization.</p><p><strong>Methods: </strong>This retrospective observational cohort study reviewed patients with ALI whom was underwent revascularization at our institution from January 2006 to December 2020. Patients with ALI in Rutherford classes I, IIa, and IIb, aged 15 years and older were included. Patients with upper extremities ischemia, patient with severity in Rutherford Class III and prior prophylactic fasciotomy were excluded from the study. The definition of post-reperfusion CS was a patient who was diagnosed with ALI and developed acute CS after revascularization.</p><p><strong>Results: </strong>Among 259 patients with acute limb ischemia, 28 (10.8%) developed post-reperfusion CS. Univariable analysis identified several risk factors, including platelet count <200,000/mm³, CK>510 U/L, serum CO<inf>2</inf><20 mmol/L, and Rutherford class IIb ischemia. Multivariable analysis confirmed independent associations for body weight >83 kg (IRR 4.24, P=0.007), moderate to severe liver disease (IRR 14.41, P<0.001), low platelet count (IRR 2.38, P=0.027), and CK>510 U/L (IRR 3.17, P=0.005). Serum CO<inf>2</inf><20 mmol/L approached significance (P=0.051). No significant differences were observed in 30-day amputation-free survival or mortality.</p><p><strong>Conclusions: </strong>Higher body weight, liver dysfunction, thrombocytopenia, and elevated CK levels are independent predictors of post-reperfusion compartment syndrome. Early identification of at-risk patients may guide monitoring and intervention to prevent this serious complication.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"366-373"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes after treatment of femoro-popliteal disease with Zilver PTX: a multicenter real-world study.","authors":"Claudio Bianchini Massoni, Ginevra Pizzarelli, Enrico Epifani, Gladiol Zenunaj, Nicola Cicala, Andrea Andreone, Aaron T Fargion, Nicola Tusini, Antonio Freyrie","doi":"10.23736/S0392-9590.25.05432-X","DOIUrl":"10.23736/S0392-9590.25.05432-X","url":null,"abstract":"<p><strong>Background: </strong>The purpose is to evaluate real-world 5-year outcomes of Cook Zilver PTX drug eluting stent (DES) in femoro-popliteal district from a multicenter experience.</p><p><strong>Methods: </strong>The retrospective observational multicenter study included patients with peripheral arterial disease treated with Zilver PTX in femoro-popliteal segment. Patients treated outside the instruction for use were excluded. We gathered patient demographics, preoperative comorbidities, clinical, arterial and stent characteristics. Target lesion revascularization (TLR) was defined as reintervention performed for ≥50%-diameter stenosis after recurrent clinical symptoms. Primary outcome was freedom from TLR (ffTLR). Secondary outcomes were stent primary patency (PP), amputation-free survival (AFS).</p><p><strong>Results: </strong>Patients were 203 (mean age: 73.5years±10.6; male:66.5%), with coronary artery disease in 93 cases (45.8%) and chronic limb-threatening ischemia (CLTI) in 154 (75.9%). Lesion length was ≥200 mm in 39 patients (19.2%), reference vessel mean diameter was 5.5±0.7 mm, lesion was a chronic total occlusion in 153 (75.4%) patients. Mean follow-up was 3.6±2.5 years. At 2, 4 and 5 years: ffTLR was 86.1%, 79.1% and 74.9%, respectively; PP was 73.7%, 64% and 61.2% and AFS was 75.1%, 64.3% and 53.4%, respectively.</p><p><strong>Conclusions: </strong>In real-world practice, Zilver PTX DES in femoro-popliteal segment reveals favorable 5-year results. Despite the high rate of CLTI patients, ffTLR and PP are comparable with already published randomized trial. However, AFS rate remains low.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"374-382"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 5-year evaluation of the GORE-TEX® Vascular Graft performance in patients undergoing treatment for abdominal aortic aneurysms.","authors":"Nabil Chakfé, Salomé Kuntz, Simon Rinckenbach, Jean Picquet","doi":"10.23736/S0392-9590.25.05435-5","DOIUrl":"10.23736/S0392-9590.25.05435-5","url":null,"abstract":"<p><strong>Background: </strong>Abdominal aortic aneurysms (AAA) open surgical repair (OSR) is still considered as a valuable option. There are no strong arguments to choose one vascular graft material and design rather than another one to perform the revascularization. The goal of the study was to evaluate the 5-year performance of the expanded polytetrafluoroethylene (ePTFE) GORE-TEX^® vascular graft for AAA OSR.</p><p><strong>Methods: </strong>We performed a retrospective, multicenter, single-arm study of patients treated with ePTFE GORE-TEX^® vascular grafts for aorto-iliac aneurysms. Patients were enrolled from three different medical centers in France. Protocol enrollment was from 2022-2023, with procedure data collected between September 2013 and January 2017. Primary endpoints included survival and primary patency at 5-years and secondary outcomes included secondary patency, infection and reinterventions rates.</p><p><strong>Results: </strong>Sixty-five patients were included. Fifty-seven percent of the patients were males and mean age was 66±7.1 years. Mean AAA diameter was 54±14 mm. Thirty-day mortality was 1.5%. Lost of follow-up rate was 1.5%. One and five-year survival rates were respectively 93.8% and 81.3%. One and five-year primary patency rates were respectively 98.5% and 96.7%. Five-year reintervention rate was 12.3%. No infection was reported.</p><p><strong>Conclusions: </strong>Our study, conducted on patients with at least a 5-year follow-up, demonstrated good results in terms of safety and durability of the use of an ePTFE graft for AAA OSR. This contemporary study contributes in the reappraisal of OSR for the management of AAA.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"401-408"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the link between post-thrombotic syndrome and depression: a narrative review on current evidence.","authors":"María Cortés, María J Medrano, Paula Huertas, Nicolas J Mouawad, Jorge H Ulloa","doi":"10.23736/S0392-9590.25.05382-9","DOIUrl":"10.23736/S0392-9590.25.05382-9","url":null,"abstract":"<p><strong>Introduction: </strong>Post-thrombotic syndrome is a chronic and challenging complication following deep venous thrombosis, that impacts a significant proportion of patients, despite anticoagulation therapy. Emerging evidence suggests a strong association between PTS and depression, with shared inflammatory mechanisms possibly linking the two conditions. This study aims to explore the potential pathophysiological connection between PTS and depression, focusing on the role of inflammatory mediators.</p><p><strong>Evidence acquisition: </strong>A comprehensive literature review was conducted across PubMed, Scopus, and Embase, analyzing articles published between 2009 to 2024. The search was divided into three phases: assessing the relationship between PTS and depressive symptoms, PTS and inflammatory mediators, and depression or depressive symptoms and inflammatory mediators. A total of 31 articles were selected based on specific inclusion criteria.</p><p><strong>Evidence synthesis: </strong>The literature search yielded 3682 articles, of which 31 met the inclusion criteria and underwent full-text review. The evidence that currently exists regarding PTS and depression is scarce, and studies have not elucidated mechanisms that explain this relationship. However, this review proposes that both depression and PTS share multiple common inflammatory markers such as IL-6, CRP and IL-10.</p><p><strong>Conclusions: </strong>The association between PTS and depression, underscores the need for integrated care approaches that address physical and mental health. Inflammation appears to be a critical link, offering a potential target for therapeutic strategies that could improve patient outcomes. Further research is necessary to fully understand this connection and develop comprehensive treatment models that address the physical and psychological aspects of PTS.</p>","PeriodicalId":13709,"journal":{"name":"International Angiology","volume":" ","pages":"341-352"},"PeriodicalIF":1.4,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145124750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}